Conference Call Today at 4:30 p.m. ET SEATTLE / Aug 14, 2025 / Business Wire / Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2025, which include: Net loss for the second quarter of 2025 was $25.4 million, or $0.43 per share, compared to a net loss of $56.0 million, or $0.97 per share for the second quarter of 2024. For... Read More

SEATTLE / Aug 11, 2025 / Business Wire / Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended June 30, 2025, on Thursday, August 14, 2025, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and... Read More

SEATTLE / Jul 25, 2025 / Business Wire / Omeros Corporation (Nasdaq: OMER) (“Omeros” or the “Company”) announced that on July 24, 2025 it entered into a securities purchase agreement with Polar Asset Management Partners to sell approximately $22 million of its common stock in a registered direct offering. Under the terms of the securities purchase agreement, the Company has agreed to sell 5,365,853 shares of its common stock... Read More

SEATTLE / Jun 27, 2025 / Business Wire / Omeros Corporation (Nasdaq: OMER) today announced the recent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). The MAA includes response-based analyses in narsoplimab-treated TA-TMA patients as well as analyses comparing... Read More

SEATTLE / Jun 24, 2025 / Business Wire / Omeros Corporation (Nasdaq: OMER) today announced that the company will host a live webcast of its Annual Meeting of Shareholders, which will be held virtually on Friday, June 27, 2025, starting at 10:00 a.m. Pacific Time. The live webcast can be accessed through the virtual shareholder meeting website at www.virtualshareholdermeeting.com/OMER2025 . A general corporate overview and... Read More

Conference Call Today at 4:30 p.m. ET SEATTLE / May 15, 2025 / Business Wire / Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2025, which include: Net loss for the first quarter of 2025 was $33.5 million, or $0.58 per share, compared to a net loss of $37.2 million, or $0.63 per share for the first quarter of 2024. At... Read More

SEATTLE / May 12, 2025 / Business Wire / Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended March 31, 2025, on Thursday, May 15, 2025, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and... Read More

SEATTLE / May 12, 2025 / Business Wire / Omeros Corporation (Nasdaq: OMER) (“Omeros” or the “Company”) today announced that it has entered into exchange agreements (the “Exchange Agreements”) with a limited number of investors who are holders of the Company’s 5.25% Convertible Senior Notes due 2026 (the “2026 Convertible Notes”) to exchange, on a one-for-one basis, $70.5 million aggregate principal amount of the 2026... Read More

SEATTLE / May 06, 2025 / Business Wire / Omeros Corporation (Nasdaq: OMER) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). The resubmission was classified as a Class 2 resubmission and pursuant to the... Read More

The Steering Committee brings together distinguished clinical experts in AML from leading National Comprehensive Cancer Network Centers SEATTLE / Apr 10, 2025 / Business Wire / Omeros Corporation (Nasdaq: OMER) today announced the establishment of the Omeros Oncology Clinical Steering Committee to advance Omeros’ OncotoX biologics program focused on acute myeloid leukemia (AML). AML is the most fatal form of leukemia and... Read More

Targeted Complement Activating Therapy™ Represents Next-Generation, Broadly Applicable Antimicrobial Therapeutics SEATTLE / Apr 08, 2025 / Business Wire / Omeros Corporation (Nasdaq: OMER) today announced that the first public presentation of its proprietary Targeted Complement Activating Therapy TM (T-CAT TM ) platform will occur at the European Congress on Infectious Diseases 2025 in Rome, Italy on Monday, April 14. The... Read More

Conference Call Today at 4:30 p.m. ET SEATTLE / Mar 31, 2025 / Business Wire / Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2024, which include: Net loss for the fourth quarter of 2024 was $31.4 million, or $0.54 per share, compared to a net loss of $32.2 million, or $0.56 per share for the third quarter of... Read More

SEATTLE / Mar 26, 2025 / Business Wire / Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter and year ended December 31, 2024, on Monday, March 31, 2025, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent... Read More

Phase 3 Data Needed for BLA Submission Expected in the Fourth Quarter 2026 SEATTLE / Mar 21, 2025 / Business Wire / Omeros Corporation (Nasdaq: OMER) today reported that clinical trial site activation for enrollment is underway for the company’s Phase 3 program evaluating zaltenibart in paroxysmal nocturnal hemoglobinuria (PNH). Zaltenibart (OMS906) is Omeros’ investigational inhibitor of MASP-3, the key and most proximal... Read More

Successful Completion of Animal Drug Interaction Studies Triggers Funding for Phase 1b Clinical Trial in Patients with CUD SEATTLE / Mar 13, 2025 / Business Wire / Omeros Corporation (Nasdaq: OMER) today announced that it has received a funding commitment from the National Institute on Drug Abuse (NIDA) for the upcoming year (April 1, 2025 through March 31, 2026) in the amount of $4.02 million for clinical development of its... Read More

Results Demonstrate Marked Survival Superiority of Narsoplimab-Treated EAP Patients, in Stand-Alone and Combined Analyses with Narsoplimab Pivotal Trial Patients, over External Control Patients Results of statistical analyses of survival in narsoplimab-treated expanded access program (EAP) TA-TMA patients compared to similarly at-risk external control registry patients were consistent with those of previously reported... Read More

SEATTLE / Feb 14, 2025 / Business Wire / Omeros Corporation (Nasdaq: OMER) today announced the availability on its website of materials accompanying two presentations given at the 2025 Tandem Meetings – the Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy and the Center for International Blood and Marrow Transplant Research. The following materials are now available... Read More

SEATTLE / Feb 10, 2025 / Business Wire / Omeros Corporation (Nasdaq: OMER) today announced two presentations that will be featured at the 2025 Tandem Meetings – the Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy and the Center for International Blood and Marrow Transplant Research, to be held February 12-15, 2025 in Honolulu, Hawaii. Both presentations report real... Read More

– Newly Completed Sensitivity Analyses Demonstrate Robustness of Previously Announced Survival Superiority Over External Control in Patients with TA-TMA – Sensitivity analyses support the results of the primary endpoint analysis, with representative sensitivity analyses demonstrating: Narsoplimab-treated patients had an over 2-fold reduction (hazard ratio = 0.42 [95% confidence interval: 0.21, 0.83]) to an over 4-fold... Read More

Primary statistical analysis of overall survival compared TA-TMA patients treated with narsoplimab in its pivotal trial to a cohort of over 100 TA-TMA patients not treated with narsoplimab in an external control stem cell transplant registry; FDA-agreed analysis was conducted by an independent external statistical group Narsoplimab-treated TA-TMA patients had an over 3-fold reduction in risk of mortality (hazard ratio = 0.32... Read More

Clinical Trial and Clinical Pharmacology Data Support Upcoming Enrollment of Omeros’ Zaltenibart Phase 3 Clinical Program in PNH SEATTLE / Dec 10, 2024 / Business Wire / Omeros Corporation (Nasdaq: OMER) today announced that two posters directed to zaltenibart (OMS906), Omeros’ investigational inhibitor of MASP-3, the key and most proximal activator of the alternative pathway of complement, were presented at the 66th Annual... Read More

Presentations Highlight Progress in Late-Stage Development of Lead MASP-3 Inhibitor Zaltenibart SEATTLE / Dec 02, 2024 / Business Wire / Omeros Corporation (Nasdaq: OMER) today announced that two abstracts directed to zaltenibart (OMS906), Omeros’ investigational inhibitor of MASP-3, the key activator of the alternative pathway of complement, will be presented at the 66th Annual Meeting of the American Society of Hematology... Read More

SEATTLE / Nov 21, 2024 / Business Wire / Omeros Corporation (Nasdaq: OMER) today announced an update on its progress toward planned resubmission of its biologics license application (“BLA”) for narsoplimab, the company’s first-in-class antibody targeting MASP-2, the effector enzyme of the lectin pathway of complement, in hematopoietic stem cell transplant-associated thrombotic microangiopathy (“TA-TMA”). In last week’s... Read More

Conference Call Today at 4:30 p.m. ET SEATTLE / Nov 13, 2024 / Business Wire / Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2024, which include: Net loss for the third quarter of 2024 was $32.2 million, or $0.56 per share, compared to a net loss of $37.8 million, or $0.60 per share for the third quarter of 2023. For... Read More

SEATTLE / Nov 11, 2024 / Business Wire / Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended September 30, 2024, on Wednesday, November 13, 2024, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments... Read More

Phase 3 Studies on the Horizon in both PNH and C3G SEATTLE / Oct 24, 2024 / Business Wire / Omeros Corporation today announced that zaltenibart (OMS906) has received rare pediatric disease designation from the U.S. Food and Drug Administration (FDA) for the treatment of complement 3 glomerulopathy (C3G), an ultra-rare, progressive renal disorder primarily afflicting children and young adults. Caused by dysregulation of the... Read More

Conference Call Today at 4:30 p.m. ET SEATTLE / Aug 07, 2024 / Business Wire / Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, as well as cancers and addictive and compulsive disorders,... Read More

SEATTLE / Aug 05, 2024 / Business Wire / Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended June 30, 2024, on Wednesday, August 7, 2024, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and... Read More

SEATTLE / Jun 04, 2024 / Business Wire / Omeros Corporation (Nasdaq: OMER) today announced that the company will host a live webcast of its Annual Meeting of Shareholders, which will be held virtually on Thursday, June 6, 2024, starting at 10:00 a.m. Pacific Time. A live webcast of the Annual Meeting of Shareholders can be accessed through www.virtualshareholdermeeting.com/OMER2024 . A general corporate overview and question... Read More

$118.1 million, or 55%, of outstanding convertible notes due in 2026 repurchased at approximately 75% of notional value, resulting in $51 million in total debt extinguishment Repurchase funded from new $67 million secured four-year term loan maturing in June 2028 together with $21 million cash on hand Credit facility includes $25 million delayed draw term loan conditionally available to fund narsoplimab commercialization... Read More

Conference Call Today at 4:30 p.m. ET SEATTLE / May 15, 2024 / Business Wire / Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders, today... Read More

SEATTLE / May 10, 2024 / Business Wire / Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter and year ended March 31, 2024, on Wednesday, May 15, 2024, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments... Read More

Interim Analysis Data from Ongoing Phase 2 Study of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Selected for Podium Presentation SEATTLE / May 09, 2024 / Business Wire / Omeros Corporation (Nasdaq: OMER) today announced that interim analysis data from its ongoing Phase 2 study of OMS906 in patients with paroxysmal nocturnal hemoglobinuria submitted to the 2024 European Hematology Association (EHA) Hybrid Congress has been... Read More

Conference Call Today at 4:30 p.m. ET SEATTLE / Apr 01, 2024 / Business Wire / Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders, today... Read More

SEATTLE / Mar 27, 2024 / Business Wire / Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter and year ended December 31, 2023, on Monday, April 1, 2024, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent... Read More

SEATTLE / Feb 20, 2024 / Business Wire / Omeros Corporation (Nasdaq: OMER) today announced the upcoming presentation of a report detailing narsoplimab treatment in nine adult patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). Narsoplimab is Omeros’ investigational antibody targeting MASP-2, the effector enzyme of the lectin pathway of the complement system. The report was... Read More

Expands DRI royalty deal on U.S. net sales of OMIDRIA Expanded deal brings Omeros $115 million upfront payment and opportunity for additional $55 million in sales-based milestones SEATTLE / Feb 01, 2024 / Business Wire / Omeros Corporation (Nasdaq: OMER) today announced the sale to DRI Healthcare Acquisitions LP (“DRI”), a wholly owned subsidiary of DRI Healthcare Trust, of an expanded interest in certain royalty payments... Read More

Conference Call Today at 1:30 p.m. ET SEATTLE / Nov 09, 2023 / Business Wire / Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders, today... Read More

SEATTLE / Nov 06, 2023 / Business Wire / Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended September 30, 2023, on Thursday, November 9, 2023, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments... Read More

Poster Presentation Slated for Upcoming Annual Meeting of the American Society of Hematology SEATTLE / Nov 03, 2023 / Business Wire / Omeros Corporation (Nasdaq: OMER) today announced online publication of a report detailing treatment with narsoplimab of 15 adult and pediatric patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), 14 of whom had “high-risk” TA-TMA. Narsoplimab is... Read More

New and Updated Data from Ongoing Phase 2 Study of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Selected for Podium Presentation SEATTLE / Nov 02, 2023 / Business Wire / Omeros Corporation (Nasdaq: OMER) today announced that two abstracts directed to OMS906, Omeros’ investigational inhibitor of MASP-3, the key activator of the alternative pathway of complement, will be presented at the 65th Annual Meeting of the American... Read More

SEATTLE / Oct 19, 2023 / Business Wire / Omeros Corporation (Nasdaq: OMER) today announced that Andreas Grauer, M.D., has been named Omeros’ chief medical officer. In his new role, Dr. Grauer will be responsible for guiding all clinical activities globally for the company, including clinical development and operations, medical affairs, safety, and biometrics. A highly tenured physician, scientist and pharmaceutical leader,... Read More

The ARTEMIS-IGAN trial did not reach statistical significance on the primary endpoint of reduction in proteinuria from baseline compared to placebo Proteinuria reduction in the placebo group was substantially greater than reported in other IgA nephropathy clinical trials Webcast conference call planned for 8:30 a.m. ET today SEATTLE / Oct 16, 2023 / Business Wire / Omeros Corporation (Nasdaq: OMER), a clinical-stage... Read More

Conference Call Today at 8:30 a.m. ET SEATTLE / Aug 09, 2023 / Business Wire / Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders, today... Read More

SEATTLE / Aug 04, 2023 / Business Wire / Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended June 30, 2023, on Wednesday, August 9, 2023, before the market opens. Omeros management will host a conference call and webcast that same day at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) to discuss the financial results as well as recent developments and... Read More

SEATTLE / Jun 21, 2023 / Business Wire / Omeros Corporation (Nasdaq: OMER), today announced that the company will host a live webcast of its Annual Meeting of Shareholders, which will be held virtually on Friday, June 23, 2023, starting at 10:00 a.m. Pacific Time. A live webcast of the Annual Meeting of Shareholders can be accessed through www.virtualshareholdermeeting.com/OMER2023 . A general corporate overview and question... Read More

SEATTLE / Jun 12, 2023 / Business Wire / Omeros Corporation (Nasdaq: OMER) today announced that the slides presented yesterday in the “late-breaker” session at the 2023 European Hematology Association (EHA) Congress in Frankfurt, Germany are now available on Omeros’ website . The presentation, which details data from a pre-specified interim analysis from the ongoing Phase 1b clinical trial of Omeros’ lead MASP-3 inhibitor... Read More

Late-breaking abstract detailing interim data from ongoing clinical trial of OMS906 in treatment-naïve PNH patients selected for June 11, 2023 oral presentation SEATTLE / Jun 01, 2023 / Business Wire / Omeros Corporation (Nasdaq: OMER) today announced that data from a pre-specified interim analysis of its ongoing Phase 1b clinical trial of OMS906, the company’s lead MASP-3 inhibitor, in complement-inhibitor-naïve adults with... Read More

Conference Call Today at 4:30 p.m. ET SEATTLE / May 09, 2023 / Business Wire / Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders, today... Read More

SEATTLE / May 04, 2023 / Business Wire / Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter financial results for the period ended March 31, 2023, on Tuesday, May 9, 2023, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent... Read More

At lowest planned subcutaneous dose, Omeros’ MASP-3 inhibitor OMS906 showed clinically and statistically significant improvements in hemoglobin and LDH, which were seen early and maintained throughout the observation period Following 2 doses of OMS906, all patients achieved an increase in hemoglobin of ³ 4.0 g/dL, with a mean... Read More

Directs Company to Advance its Lead Proprietary PDE7 Inhibitor to Treat Cocaine Use Disorder SEATTLE / Apr 10, 2023 / Business Wire / Omeros Corporation (Nasdaq: OMER) today announced that it has been awarded a grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, to develop Omeros’ lead orally administered compound from its proprietary phosphodiesterase 7 (PDE7) program OMS527... Read More

SEATTLE / Mar 10, 2023 / Business Wire / Omeros Corporation (Nasdaq: OMER), in response to investor inquiries, is confirming that it has no banking or other financial relationship with Silicon Valley Bank. Omeros previously maintained a line of credit with Silicon Valley Bank, which the company allowed to expire in August 2022. Omeros does not have any assets on deposit with Silicon Valley Bank, nor does the company maintain... Read More

SEATTLE / Mar 07, 2023 / Business Wire / Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its fourth quarter and year-end financial results for the period ended December 31, 2022, on Monday, March 13, 2023, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as... Read More

SEATTLE / Feb 06, 2023 / Business Wire / Omeros Corporation (Nasdaq: OMER) today announced that Rayner Surgical, Inc. (“Rayner”) has paid the $200 million milestone payment due to Omeros under the Asset Purchase Agreement, dated December 1, 2021 (the “Agreement”), pursuant to which Omeros sold its ophthalmology product OMIDRIA ® to Rayner in December of 2021. The Milestone Event, as defined in the Agreement, occurred in late... Read More